Loading
A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors is a phase 2 interventional study registered as NCT03964727 by Gilead Sciences, with 227 participants enrolled, started 2019-10-15 and due to reach its primary completion in 2025-01-15. Interventions recorded: Sacituzumab Govitecan-hziy. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
227 enrolled.
95% CI 3.6 to 29.8; Figures from the ClinicalTrials.gov results section (first posted 2026-01-30), not from a publication · 95% CI 0.7 to 19.7 · 95% CI 0.8 to 21.4 · 95% CI 6.8 to 30.7 · 95% CI 14.2 to 42.9 · 95% CI 29.1 to 60.1
Source95% CI 4.34 to 23.72; Figures from the ClinicalTrials.gov results section (first posted 2026-01-30), not from a publication · 95% CI 4.24 to 20.47 · 95% CI 5.16 to 10.22 · 95% CI 7.52 to 12.22 · 95% CI 5.88 to 21.42 · 95% CI 6.57 to 14.72
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessmentprimary | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | 31 | 12.9% | - | - | link |
| Cohort 1 Group 2: NSCLC (Adenocarcinoma) | 34 | 5.9% | ||||
| Cohort 1 Group 3: NSCLC (SCC) | 31 | 6.5% | ||||
| Cohort 2: HNSCC | 43 | 16.3% | ||||
| Cohort 3: EC | 41 | 26.8% | ||||
| Cohort 4: ES-SCLC | 43 | 44.2% | ||||
| Overall Survival (OS) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | 31 | 14.26 months | - | - | link |
| Cohort 1 Group 2: NSCLC (Adenocarcinoma) | 34 | 11.02 months | ||||
| Cohort 1 Group 3: NSCLC (SCC) | 31 | 7.29 months | ||||
| Cohort 2: HNSCC | 43 | 8.97 months | ||||
| Cohort 3: EC | 41 | 14.95 months | ||||
| Cohort 4: ES-SCLC | 43 | 11.73 months |
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.